I.S. Chernomaz – 

Post-graduate Student, Department of Clinical Biochemistry and Laboratory Diagnostics, 

A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow)

I.V. Babkina – 

Dr.Sc. (Med.), Professor, Department of Clinical Biochemistry and Laboratory Diagnostics, 

A.I. Evdokimov Moscow State Medical and Dental University of the Ministry of Health of Russia (Moscow) E-mail: docbabkina@rambler.ru

E.S. Gershtein – 

Dr.Sc. (Biol.), Professor, Leading Research Scientist,

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

A.V. Bondarev – 

Oncologist, Moscow Oncological Hospital № 62 (Moscow)

Yu. M. Shchupak – 

Oncologist, Head of Surgical Department, Moscow Oncological Hospital № 62 (Moscow)

I.V. Boulitcheva – 

Dr.Sc. (Med.), Pathologist, 

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

M.D. Aliev – 

Dr.Sc. (Med.), Professor, Academician of RAS, Advisor to the Director of the Scientific Research Center for Radiology, Ministry of Health of Russia, 

President of the «East European Group for the Study of Sarcomas» (Moscow)

Ewing sarcoma is the second the most common malignant bone tumor in young patients, while chondrosarcoma is more often found in another age group – those over 30 years. Addition of new drugs to the standard chemotherapeutic regimens could not as yet significantly improve treatment results in both tumor types. Therefore, investigation of new molecular targets for the therapy of both Ewing sarcoma and chondrosarcoma remains an important task of modern clinical oncology. Aim of the study – investigation of the influence of pre-treatment MMP-2, 7, 9 and their type 1 and 2 tissue inhibitors (TIMP1, 2) serum levels on the overall and relapse-free survival of Ewing and chondrosarcoma patients for evaluation of possible associations of the markers’ levels with tumor morphologic structure and disease prognosis.

29 chondrosarcoma, 15 Ewing sarcoma patients and 76 age-matched healthy persons comprising control group were enclosed in the study. In all the patients the diagnosis was primary established and confirmed by histological examination data. MMP-2, 7, 9, TIMP-1 and 2 concentrations were measured in blood serum obtained before the onset of specific treatment with the help of ELISA kits produced by «R&D» (USA). «Statistica» 7.0 program was applied for evaluation of the data. Significant differences from control were revealed for MMP-2, MMP-7 and TIMP-2 serum levels in chondrosarcoma patients, and for MMP-2, MMP-9 and TIMP-in those with Ewing sarcoma, the difference being probably associated with the biologic peculiarities of the growth of these neoplasms. In chondrosarcoma significant (р = 0,044) differences in relapse-free survival depending on the MMP-7 serum level were found: in patients with MMP-7 level <3.4 ng/ml no disease progression was observed throughout 10 years’ follow-up period, while in patients with MMP-7 ≥3.4 ng/ml 5-years relapse-free survival comprised 33,7±24,7% with the median of remission duration 43 months. No statistically significant differences in both relapsefree and overall survival of Ewing sarcoma patients in relation to the parameters studied were detected. However, 3-years relapse-free survival of patients with serum TIMP-1 <343 ng/ml comprised 84,6±9,8%, and in those with TIMP-1 ≥343 ng/ml – 27,8±16,4%.

The results evidence in favor of further investigation of ММП-2, 7, 9, and TIMP-1, 2 circulating in peripheral blood of Ewing and chondrosarcoma patients as potential markers of disease prognosis.

1. Gazula S., Rani V.L., Jonathan G.T., Kumar N.N. Extraskeletal Ewing’s Sarcoma Masquerad-ing as Infantile Benign Neck Mass // J. Indian Assoc. Pediatr. Surg. 2019. V. 24. № 3. P. 209–211.
2. Patel P.O., Pishas K.I., Taslim C., Selich-Anderson J., Theisen E.R., Lessnick S.L. Investigating the role of LSD2 as an epigenetic regulator in Ewing sarcoma // Oncotarget. 2019. V. 10. № 39. P. 3865–3878.
3. Tamura A., Yamamoto N., Nino N., Ichikawa T., Nakatani N., Nakamura S., Saito A., Kozaki A., Kishimoto K., Ishida T., Yoshida M., Akasaka Y., Hasegawa D., Kosaka Y. Pazopanib mainte-nance therapy after tandem high-dose chemotherapy for disseminated Ewing sarcoma // Int. Cancer Conf. J. 2019. V. 8. № 3. P. 95–100.
4. Li G., Zhang P., Zhang W., Lei Z., He J., Meng J., Di T., Yan W. Identification of key genes and pathways in Ewing’s sarcoma patients associated with metastasis and poor prognosis // Onco Targets Ther. 2019. V. 12. P. 4153–4165.
5. Mao W., Kong M., Yu H., Wang D., Huang X., Yao X., Fan J., Geng J. Prognosis and treatment differences between initial and second primary chondrosarcoma // Oncol. Lett. 2019. V. 18. № 1. P. 207–218.
6. Capasso L., Florio M., Lillo M., Basilico M., De Santis V., Ziranu A., Grasso A., Minutillo F., Maccauro G. Vascular endothelial growth factor expression as a biomarker of prognosis in patients with chondrosarcoma, Ewing's sarcoma and osteosarcoma. Current concepts // J. Biol. Regul. Homeost. Agents. 2019. V. 33. (2 Suppl. 1). P. 39–43.
7. Gershtejn E.S., Kushlinskij D.N., Adamyan L.V., Tereshkina I.V., Laktionov K.P. Mat-riksnye metalloproteinazy i ih tkanevye ingibitory v klinicheskom techenii i prognoze raka yaichnikov // Molekulyarnaya medicina. 2013. № 6. S. 11–20.
8. Malcherczyk D., Heyse T.J., El-Zayat B.F., Kunzke V., Moll R., Fuchs-Winkelmann S., Paletta J.R.J. Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohisto-chemical study // BMC Musculoskelet Disord. 2018. V. 19. № 1. P. 9. DOI: 10.1186/s12891-0171920-7.
9. Cecen B., Keles D., Oktay G., Kozaci L.D. Effects of simvastatin on matrix metalloproteinase regulation in IL-1β-induced SW1353 cells // Chem. Biol. Interact. 2019. V. 310:108730. DOI: 10.1016/j.cbi.2019.108730.
10. Yao M., Wang X., Zhao Y., Wang X., Gao F. Expression of MMPs is dependent on the activity of mitogen-activated protein kinase in chondrosarcoma // Mol. Med. Rep. 2017. V. 15. № 2. P. 915–921.
11. Ye C., Yu X., Zeng J., Dai M., Zhang B. Effects of baicalein on proliferation, apoptosis, migra-tion and invasion of Ewing’s sarcoma cells // Int. J. Oncol. 2017. V. 51. № 6. P. 1785–1792.
12. Kushlinskij N.E., Solov'ev YU.N., Babkina I.V., Gershtejn E.S., Bulycheva I.V. Matriks-nye metalloproteinazy 2, 7, 9 i tkanevoj ingibitor matriksnyh metalloproteinaz 1-go ti-pa v syvorotke krovi bol'nyh opuholyami kostej // Byulleten' eksperimental'noj biologii i mediciny. 2010. T. 149. № 2.  S. 194–196.
13. Babkina I.V., Bondarev A.V., SHCHupak M.YU., Bulycheva I.V., Solov'ev YU.N., Mahson A.N. Otdalennye rezul'taty lecheniya bol'nyh sarkomami kostej s uchetom soderzhaniya metallo-proteinaz v syvorotke krovi // Al'manah klinicheskoj mediciny. 2015. T. 41. S. 40–45.
14. Babkina I.V., CHernomaz I.S., Gershtejn E.S., Kuznecov I.N., Bondarev A.V., SHCHupak M.YU., Solov'ev YU.N., Bulycheva I.V., Aliev M.D., Kushlinskij N.E. Otdalennye rezul'taty lecheniya bol'nyh osteosarkomoj kosti s uchetom soderzhaniya matriksnyh metalloproteinaz i ih tkanevyh ingibitorov v syvorotke krovi // Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2019. T. 22. № 2. S. 35–42.